有効性評価に基づく前立腺がん検診ガイドライン

添付書類2

添付書類2：最終追加文献リスト　委員会20文献（AF1）+USPSTF5文献（治療不利益）+久道班1文献+外部評価委員9文献＝35文献

ガイドライン引用No	追加要因	Auther	Title	Journal	Volumes	Issue	Pages	Year
24	委員会	Friedman GD, Hiatt RA, Quesenberry CP Jr, Selby JV.	Case-control study of screening for prostatic cancer by digital rectal examinations.	Lancet	337		1526-9	1991
25	委員会	Richert-Boe KE, Humphrey LL, Glass AG, Weiss NS.	Screening digital rectal examination and prostate cancer mortality: a case-control study.	J Med Screen	5	2	99-103	1998
27	委員会	Jacobsen SJ, Bergstralh EJ, Katusic SK, Guess HA, Darby CH, Silverstein MD, Oesterling JE, Lieber MM.	Screening digital rectal examination and prostate cancer mortality: a population-based case-control study.	Urology	52	2	173-9	1998
32	委員会（コクランSR引用文献）	Sandblom G, Varenhorst E, Löfman O, Rosell J, Carlsson P.	Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden.	Eur Urol	46		717-24	2004
33	委員会	Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J.	Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.	Eur Urol	51	3	659-64	2007
37	委員会	Concato J, Wells CK, Horwitz RI, Penson D, Fincke G, Berlowitz DR, Froehlich G, Blake D, Vickers MA, Gehr GA, Raheb NH, Sullivan G, Peduzzi P.	The effectiveness of screening for prostate cancer: a nested case-control study.	Arch Intern Med	166		38-43	2006
38	委員会	Kopec JA, Goel V, Bunting PS, Neuman J, Sayre EC, Warde P, Levers P, Fleshner N.	Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study.	J Urol	174		495-9	2005
41	委員会	Coldman AJ, Phillips N, Pickles TA.	Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity.	CMAJ	168	1	31-5	2003
43	委員会	Threlfall TJ, English DR, Rouse IL.	Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996.	Med J Aust	169		21-4	1998
44	委員会	Skarsgard D, Tonita J.	Prostate cancer in Saskatchewan Canada, before and during the PSA era.	Cancer Causes Control	11		79-88	2000
45	委員会	Majeed A, Babb P, Jones J, Quinn M.	Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998.	BJU Int	85		1058-62	2000
46	委員会	Post PN, Kil PJ, Crommelin MA, Schapers RF, Coebergh JW.	Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in southeastern Netherlands, 1971-1995.	Eur J Cancer	34	5	705-9	1998
47	委員会	Brewster DH, Fraser LA, Harris V, Black RJ.	Rising incidence of prostate cancer in Scotland: increased risk or increased detection?	BJU Int	85		463-73	2000
48	委員会	Roberts RO, Bergstralh EJ, Katusic SK, Lieber MM, Jacobsen SJ.	Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota.	J Urol	161		529-33	1999
50	委員会	Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ.	Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States.	Cancer Epidemiol Biomarkers Prev	14	3	590-5	2005
51	委員会	Baade PD, Coory MD, Aitken JF.	International trends in prostate-cancer mortality: the decrease is continuing and spreading.	Cancer Causes Control	15		237-41	2004
66	久31	Kubota Y, Ito K, Imai K, Yamanaka H.	Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities.	Prostate	50	4	262-9	2002
76	外部評価委員	Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, Graham E, Echols RM, Whalen E, Kowalsky SF.	Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy.	Urology	52	4	552-8	1998
77	外部評価委員	Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD.	Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. 1990.	J Urol	167	2 Pt 2	966-75	2002
78	外部評価委員	Rodríguez LV, Terris MK.	Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature.	J Urol	160	6 Pt 1	2115-20	1998
79	外部評価委員	Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, Borkowski A, Schulman C, Marberger M.	Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study.	J Urol	166	3	856-60	2001
81	外部評価委員	Crawford ED, Haynes AL Jr, Story MW, Borden TA.	Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy.	J Urol	127	3	449-51	1982
82	外部評価委員	Aron M, Rajeev TP, Gupta NP.	Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study.	BJU Int	85	6	682-5	2000
83	外部評価委員	Norberg M, Holmberg L, Häggman M, Magnusson A.	Determinants of complications after multiple transrectal core biopsies of the prostate.	Eur Radiol	6	4	457-61	1996
84	外部評価委員	熊谷章，小川大輔，小山敏樹，竹内一郎，大山格．	経直腸的前立腺生検後にフルニエ壊疽を発症した管理不良な糖尿病患者の1例．	日本泌尿器科学会雑誌	93	5	648-51	2002
85	外部評価委員	長谷川太郎，下村達也，山田裕紀，伊藤博之，加藤伸樹，長谷川倫男，浅野晃司，清田浩，池本庸，小野寺昭一，大石幸彦．	経直腸的前立腺針生検による敗血症性ショックの1死亡例．	感染症学雑誌	76	10	893-7	2002
86	USPSTF	Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL.	Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study.	JAMA	283	3	354-60	2000
87	委員会	Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, Kupelian PA.	The use of treatments for erectile dysfunction among survivors of prostate carcinoma.	Cancer	95	11	2397-407	2002
88	USPSTF	Lu-Yao GL, McLerran D, Wasson J, Wennberg JE.	An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team.	JAMA	269	20	2633-6	1993
89	USPSTF	Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlén BJ, Holmberg L; Scandinavian Prostatic Cancer Group Study Number 4.	Quality of life after radical prostatectomy or watchful waiting.	N Engl J Med	347	11	790-6	2002
90	委員会	Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC.	Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.	J Natl Cancer Inst	96	18	1358-67	2004
91	USPSTF	Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC.	Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.	J Natl Cancer Inst	92	19	1582-92	2000
93	USPSTF	Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, Wishnow KI, Kaplan I, Loughlin KR, Richie JP, Kantoff PW.	Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study.	J Clin Oncol	16	1	275-83	1998
94	委員会	Arai Y, Egawa S, Tobisu K, Sagiyama K, Sumiyoshi Y, Hashine K, Kawakita M, Matsuda T, Matsumoto K, Fujimoto H, Okada T, Kakehi Y, Terachi T, Ogawa O.	Radical retropubic prostatectomy: time trends, morbidity and mortality in Japan.	BJU Int	85	3	287-94	2000
95	委員会	Hisasue S, Takahashi A, Kato R, Shimizu T, Masumori N, Itoh N, Tsukamoto T.	Early and late complications of radical retropubic prostatectomy: experience in a single institution.	Jpn J Clin Oncol	34	5	274-9	2004

<前へ次へ>

目次タイトル
メモ（任意）

有効性評価に基づく前立腺がん検診ガイドライン

ガイドライン解説

診療ガイドライン検索